Showing 1 to 1 of 1 results
theguardian.com
🌐 85% Global Worthiness
New Alzheimer's Drugs Show Promise but Face Accessibility Barriers
New Alzheimer's drugs, lecanemab and donanemab, slow disease progression by about 30% but are expensive (£20,000-£25,000 annually), require specialized administration and monitoring, and are therefore inaccessible to most of the world's 50 million dementia sufferers, two-thirds of whom live in low- ...
New Alzheimer's Drugs Show Promise but Face Accessibility Barriers
New Alzheimer's drugs, lecanemab and donanemab, slow disease progression by about 30% but are expensive (£20,000-£25,000 annually), require specialized administration and monitoring, and are therefore inaccessible to most of the world's 50 million dementia sufferers, two-thirds of whom live in low- ...
Progress
36% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results